Celldex Therapeutics (CLDX) Shares Outstanding (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Shares Outstanding (Entity) of $66.6 million for Q1 2026, up 100180.15% year-over-year from N/an in Q1 2025, and little changed quarter-over-quarter from $66.5 million in Q4 2025.
Celldex Therapeutics (CLDX) Shares Outstanding (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $66.6 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 100180.15% year-over-year to $66.6 million; the TTM figure through Mar 2026 stood at $66.6 million (up 100180.15% YoY), while the FY2025 annual figure was $66.5 million, up 103245.67% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $66.6 million, roughly flat from $66.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $66.6 million in Q1 2026, with the low at $46888.0 in Q4 2022.
- The 5-year median for Shares Outstanding (Entity) is $66294.0 (2024), against an average of $16.1 million.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) sank 99.9% in 2023, then soared 103245.67% in 2025.
- Celldex Therapeutics' Shares Outstanding (Entity) stood at $46888.0 in 2022, then grew by 3.33% to $48449.0 in 2023, then soared by 32.91% to $64395.0 in 2024, then jumped by 103245.67% to $66.5 million in 2025, then climbed by 0.03% to $66.6 million in 2026.
- Business Quant data shows CLDX's Shares Outstanding (Entity) at $66.6 million in Q1 2026, $66.5 million in Q4 2025, and $66420.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 77.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.84 Mn |
| Mar 31, 2026 | 66.57 Mn |
| Dec 31, 2025 | 66.42 Mn |
| Sep 30, 2025 | 66,420.00 |
| Jun 30, 2025 | 66,392.00 |
| Mar 31, 2025 | 66,383.00 |
| Dec 31, 2024 | 64,395.00 |
| Sep 30, 2024 | 66,294.00 |
| Jun 30, 2024 | 66,019.00 |
| Mar 31, 2024 | 58,871.00 |
| Dec 31, 2023 | 48,449.00 |
| Sep 30, 2023 | 47,261.00 |
| Jun 30, 2023 | 47,253.00 |
| Mar 31, 2023 | 47,214.00 |
| Dec 31, 2022 | 46,888.00 |
| Sep 30, 2022 | 46.92 Mn |
| Jun 30, 2022 | 46.76 Mn |
| Mar 31, 2022 | 46.74 Mn |
| Dec 31, 2021 | 42,870.00 |
| Sep 30, 2021 | 45.45 Mn |